. Author manuscript; available in PMC: 2019 Jul 25.

Published in final edited form as: Nat Rev Gastroenterol Hepatol. 2014 Apr 1;11(7):402–409. doi: 10.1038/nrgastro.2014.30

Table 1 |.

Current FDA-approved therapies for treatment of HBV⁶³

Generic Name	Indication	FDA pregnancy category
Interferon α−2b	Chronic HBV, aged ≥1 year, compensated disease	C^*
Interferon	Adult patients with HBV (HBeAg positive or negative) with compensated disease, viral replication and liver inflammation	C^*
Lamivudine	Chronic HBV with viral replication and liver inflammation	C^*
Adefovir dipivoxil	Chronic HBV, aged ≥12 years	C^*
Entecavir	Chronic HBV with active viral replication	C^*
Tenofovir disoproxil fumarate	Chronic HBV in adults	B^‡
Telbivudine	Chronic HBV in adults with viral replication and transaminitis or histological activity	B^‡

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

^‡

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.